"Cisplatin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle.
| Descriptor ID |
D002945
|
| MeSH Number(s) |
D01.210.375 D01.625.125 D01.710.100
|
| Concept/Terms |
Cisplatin- Cisplatin
- cis-Diamminedichloroplatinum(II)
- Platinum Diamminodichloride
- Diamminodichloride, Platinum
- cis-Platinum
- cis Platinum
- Dichlorodiammineplatinum
- cis-Diamminedichloroplatinum
- cis Diamminedichloroplatinum
- cis-Dichlorodiammineplatinum(II)
|
Below are MeSH descriptors whose meaning is more general than "Cisplatin".
Below are MeSH descriptors whose meaning is more specific than "Cisplatin".
This graph shows the total number of publications written about "Cisplatin" by people in this website by year, and whether "Cisplatin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 10 | 20 | 30 |
| 1995 | 9 | 20 | 29 |
| 1996 | 6 | 19 | 25 |
| 1997 | 8 | 24 | 32 |
| 1998 | 8 | 28 | 36 |
| 1999 | 7 | 29 | 36 |
| 2000 | 7 | 21 | 28 |
| 2001 | 4 | 28 | 32 |
| 2002 | 7 | 34 | 41 |
| 2003 | 18 | 34 | 52 |
| 2004 | 5 | 38 | 43 |
| 2005 | 8 | 30 | 38 |
| 2006 | 9 | 31 | 40 |
| 2007 | 14 | 31 | 45 |
| 2008 | 17 | 32 | 49 |
| 2009 | 6 | 29 | 35 |
| 2010 | 9 | 28 | 37 |
| 2011 | 13 | 29 | 42 |
| 2012 | 9 | 24 | 33 |
| 2013 | 16 | 32 | 48 |
| 2014 | 11 | 29 | 40 |
| 2015 | 14 | 30 | 44 |
| 2016 | 12 | 23 | 35 |
| 2017 | 14 | 22 | 36 |
| 2018 | 13 | 12 | 25 |
| 2019 | 21 | 13 | 34 |
| 2020 | 8 | 23 | 31 |
| 2021 | 4 | 20 | 24 |
| 2022 | 3 | 21 | 24 |
| 2023 | 4 | 13 | 17 |
| 2024 | 7 | 4 | 11 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cisplatin" by people in Profiles.
-
The cochlear dose and the age at radiotherapy predict severe hearing loss after passive scattering proton therapy and cisplatin in children with medulloblastoma. Neuro Oncol. 2024 Oct 03; 26(10):1912-1920.
-
Results of a randomized phase II trial of paclitaxel and carboplatin versus bleomycin, etoposide and cisplatin for newly diagnosed and recurrent Chemonaive stromal ovarian tumors: An NRG oncology/gynecologic oncology group study14. Gynecol Oncol. 2024 Nov; 190:283-290.
-
A Phase I Open-Label Study of Cediranib Plus Etoposide and Cisplatin as First-Line Therapy for Patients With Extensive-Stage Small-Cell Lung Cancer or Metastatic Neuroendocrine Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2024 Nov; 25(7):601-611.
-
Personalized Chemotherapy on the Basis of Tumor Marker Decline in Poor-Prognosis Germ-Cell Tumors: Updated Analysis of the GETUG-13 Phase III Trial. J Clin Oncol. 2024 Oct; 42(28):3270-3276.
-
Correlative Analysis of ATM, RB1, ERCC2, and FANCC Mutations and Pathologic Complete Response After Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer: Results from the SWOG S1314 Trial. Eur Urol. 2024 Oct; 86(4):297-300.
-
Radiation Therapy With or Without Cisplatin for Local Recurrences of Endometrial Cancer: Results From an NRG Oncology/GOG Prospective Randomized Multicenter Clinical Trial. J Clin Oncol. 2024 Jul 10; 42(20):2425-2435.
-
p90RSK pathway inhibition synergizes with cisplatin in TMEM16A overexpressing head and neck cancer. BMC Cancer. 2024 Feb 19; 24(1):233.
-
Systemic Cisplatin Does Not Affect the Bone Regeneration Process in a Critical Size Defect Murine Model. ACS Biomater Sci Eng. 2024 03 11; 10(3):1646-1660.
-
Association of Molecular Subtypes with Pathologic Response, PFS, and OS in a Phase II Study of COXEN with Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. Clin Cancer Res. 2024 01 17; 30(2):444-449.
-
SH3RF2 contributes to cisplatin resistance in ovarian cancer cells by promoting RBPMS degradation. Commun Biol. 2024 01 09; 7(1):67.